ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Little Relation of Cancer Incidence To Known Carcinogens Except For Cigarettes, Holleb Says

July 14, 1978

In Brief: Greenwald Named Director, NCI Prevention; Wells Directs American College Of Surgeons

June 19, 1998

In Brief: David Nathan receives Lifetime Impact Award from Boston Children’s Hospital

November 7, 2014

Smoking, Drinking Factors Affect Adherence to Preventive Regimen

September 30, 2011

mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients

February 25, 2011

ACS Awards Grants Totaling $31.3 Million

January 25, 1985